Skip to Content
Merck
CN
  • Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.

Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.

Bioorganic & medicinal chemistry (2008-05-17)
Mojca Brunskole, Bogdan Stefane, Karmen Zorko, Marko Anderluh, Jure Stojan, Tea Lanisnik Rizner, Stanislav Gobec
ABSTRACT

Trihydroxynaphthalene reductase (3HNR) is an essential enzyme in the biosynthesis of fungal melanin and it represents an emerging target for the development of new fungicides and antimicotics. To promote the discovery of new inhibitors, an improved chemical synthesis of the artificial substrate 2,3-dihydro-2,5-dihydroxy-4H-benzopyran-4-one (DDBO) was developed. A series of compounds were screened on 3HNR from Curvularia lunata, a known plant pathogen and an opportunistic human pathogen, and several structurally diverse hits were obtained. Homology modelling of 3HNR from C. lunata can explain their binding modes and will enable further structure-based design of new and improved inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1,3-Indandione, 97%
Sigma-Aldrich
Diclofenac sodium salt
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Sigma-Aldrich
Phenacetin, ≥98.0% (HPLC)
Supelco
Ibuprofen
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
Supelco
Naproxen, VETRANAL®, analytical standard
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Sigma-Aldrich
Ketoprofen, meets USP testing specifications
Sigma-Aldrich
Naproxen, meets USP testing specifications